Preresection serum C-reactive protein measurement and survival among patients with resectable non–small cell lung cancer Marco Alifano, MD, PhD, Pierre.

Slides:

Advertisements

Similar presentations

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

Advertisements

Lost in translation The Journal of Thoracic and Cardiovascular Surgery

Manuel J. Antunes, MD, PhD, DSc

Stephen R. Broderick, MD, MPHS

Tumor angiogenesis in predicting the survival of patients with stage I lung cancer Baris Medetoglu, MD, Mehmet Zeki Gunluoglu, MD, Adalet Demir, MD, Huseyin.

Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis? Atsushi Watanabe, MD, PhD, Tetsuya Higami, MD, PhD, Syunsuke Ohori,

The eighth edition TNM stage classification for lung cancer: What does it mean on main street? Frank C. Detterbeck, MD The Journal of Thoracic and Cardiovascular.

Michael Y. Chang, MD, MPH, Steven J. Mentzer, MD, Yolonda L

Mitral stenosis with pulmonary hypertension: We should operate early

Local recurrence after surgery for non–small cell lung cancer: A recursive partitioning analysis of multi-institutional data Chris R. Kelsey, MD, Kristin.

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible Alessandro Brunelli,

Effect of tumor size on prognosis in patients with non–small cell lung cancer: The role of segmentectomy as a type of lesser resection Morihito Okada,

Long-Term Results after Treatment for Recurrent Thymoma: A Multicenter Analysis Alberto Sandri, Giacomo Cusumano, Filippo Lococo, MD, Marco Alifano, Pierluigi.

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Paul J. Scheel, BS, Traves D. Crabtree, MD, Jennifer M

Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system Shamus R.

Which patients should be operated on after induction chemotherapy for N2 non–small cell lung cancer? Analysis of a 7-year experience in 175 patients

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Surgical treatment is decisive for outcome in chondrosarcoma of the chest wall: A population-based Scandinavian Sarcoma Group study of 106 patients Björn.

Prognostic evaluation based on a new TNM staging system proposed by the International Association for the Study of Lung Cancer for resected non–small.

Lobectomy with pulmonary artery resection: Morbidity, mortality, and long-term survival Marco Alifano, MD, Giacomo Cusumano, MD, Salvatore Strano, MD,

Body Mass Index and Total Psoas Area Affect Outcomes in Patients Undergoing Pneumonectomy for Cancer Remi Hervochon, MD, Antonio Bobbio, MD, PhD, Claude.

The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer Kyong-Ah Yoon,

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer Hong.

Survival after resection of synchronous non–small cell lung cancer

The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer Francesco Sclafani,

Sleeve lung resection for lung cancer: Analysis according to the type of procedure Kazumichi Yamamoto, MD, Yoshihiro Miyamoto, MD, Akihiro Ohsumi, MD,

Interstitial tumor-associated macrophages combined with tumor-derived colony- stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non–small.

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

The lord of the rings Antonio Miceli, MD, PhD

Esophagectomy versus endoscopic resection for patients with early-stage adenocarcinoma: Mercedes versus Tesla Toni Lerut, MD The Journal of Thoracic.

Elizabeth A. David, MD, MAS, Stina W. Andersen, PhD, Laurel A

Yang Zhang, MD, Haiquan Chen, MD, PhD

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

It's not “just a shunt” but sometimes it should be…

A first start for lung transplantation?

Stephen R. Broderick, MD, MPHS

Are discordant positron emission tomography and pathological assessments of the mediastinum in non–small cell lung cancer significant? Daniel J. Tandberg,

Resection of primary lung cancer with incidental pleural seeding: Seeds of change or reap what you sow? Jules Lin, MD The Journal of Thoracic and Cardiovascular.

It’s All in the “Swerve of the Curve”

Adjuvant Surgery after Carboplatin and VP16 in Resectable Small Cell Lung Cancer Giulia Veronesi, MD, Paolo Scanagatta, MD, Francesco Leo, MD, Tommaso.

Video-assisted resection for lung cancer results in fewer complications Lunxu Liu, PhD, MD, FRCS The Journal of Thoracic and Cardiovascular Surgery

Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: The Japan Clinical.

Passing the torch The Journal of Thoracic and Cardiovascular Surgery

Video-assisted mediastinoscopic lymphadenectomy is associated with better survival than mediastinoscopy in patients with resected non–small cell lung.

Development of a patient-centered aggregate score to predict survival after lung resection for non–small cell lung cancer Alessandro Brunelli, MD, Michele.

Bryan M. Burt, MD The Journal of Thoracic and Cardiovascular Surgery

Sebastien Gilbert, MD, Andre B. Martel, BSc, Andrew J

Long-term results of Freestyle stentless bioprosthesis in the aortic position: A single- center prospective cohort of 500 patients Nicolas Amabile, MD,

Jeffrey H. Shuhaiber, MD, Jeff Moore, MS, David B. Dyke, MD

Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis Mariette Baud, MD, Salvatore Strano, MD, PhD, Agnes.

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

The future of cardiac surgery training: A survival guide

Linda W. Martin, MD, MPH, FCCP, FACS, Gail E

Robert J. Cerfolio, MD, FACS, FCCP, Ayesha S. Bryant, MSPH, MD

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

“The more things change…”: The challenges ahead

Aritoshi Hattori, MD, Kenji Suzuki, MD

Salvage surgery for advanced non–small cell lung cancer after response to gefitinib Tomoyuki Hishida, MD, Kanji Nagai, MD, Tetsuya Mitsudomi, MD, Kohei.

Carcinoma showing thymus-like elements invading the trachea

Who should decide margin length in pulmonary excision of lung cancer?

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Is there a benefit to continuing with resection of all sites of disease when clinically occult pleural metastases from non–small cell carcinoma are found?

Samuel Kim, MD The Journal of Thoracic and Cardiovascular Surgery

Reappraise the advanced technique for tumor localization and sentinel lymph node assessment in clinical early-stage non–small cell lung cancer Chengwu.

Deciding how much to pay for effective care

Kristin A. Higgins, MD, Junzo P. Chino, MD, Neal Ready, MD, Mark W

Presentation transcript:

Preresection serum C-reactive protein measurement and survival among patients with resectable non–small cell lung cancer Marco Alifano, MD, PhD, Pierre E. Falcoz, MD, PhD, Valérie Seegers, MD, Nicolas Roche, MD, PhD, Olivier Schussler, MD, PhD, Mohamad Younes, MD, Filippo Antonacci, MD, Patricia Forgez, PhD, Agnes Dechartres, MD, Gilbert Massard, MD, Diane Damotte, MD, PhD, Jean-François Régnard, MD The Journal of Thoracic and Cardiovascular Surgery Volume 142, Issue 5, Pages 1161-1167 (November 2011) DOI: 10.1016/j.jtcvs.2011.07.021 Copyright © 2011 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 Kaplan-Meier estimates of survival. A, Overall survival in the main cohort. B, Survival curves of patients with stages I and II in the main cohort according to the C-reactive protein (CRP) levels. C, Survival curves of patients with stages III and IV in the main cohort according to the C-reactive protein levels. D, Survival curves in the validation cohort according to the C-reactive protein levels. The Journal of Thoracic and Cardiovascular Surgery 2011 142, 1161-1167DOI: (10.1016/j.jtcvs.2011.07.021) Copyright © 2011 The American Association for Thoracic Surgery Terms and Conditions